

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104  
Estimated average burden  
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Macaluso Peter M</u>	2. Date of Event Requiring Statement (Month/Day/Year) 02/01/2013	3. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC [ FOLD ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP &amp; Corporate Counsel</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) <u>1 CEDAR BROOK DRIVE</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>CRANBURY NJ 08512</u>			
(City) (State) (Zip)			

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (right to buy)	08/01/2012	08/06/2018	Common Stock	10,000	16.71	D	
Stock Options (right to buy)	02/01/2013	02/03/2019	Common Stock	7,000	10.36	D	
Stock Options (right to buy)	(1)	11/16/2019	Common Stock	15,000	4.16	D	
Stock Options (right to buy)	(2)	03/16/2020	Common Stock	10,000	3.32	D	
Stock Options (right to buy)	(3)	06/15/2020	Common Stock	10,000	2.81	D	
Stock Options (right to buy)	(4)	01/19/2021	Common Stock	12,500	5.96	D	
Stock Options (right to buy)	(5)	06/16/2021	Common Stock	17,500	6.06	D	
Stock Options (right to buy)	(6)	02/15/2022	Common Stock	12,500	6.45	D	
Stock Options (right to buy)	(6)	06/04/2022	Common Stock	12,500	4.38	D	
Stock Options (right to buy)	(7)	01/28/2023	Common Stock	35,000	3.53	D	

## Explanation of Responses:

- These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vested on November 16, 2010. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on December 1, 2010, with the final installment vesting on November 1, 2013.
- These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on March 16, 2011. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on April 1, 2011, with the final installment vesting on March 1, 2014.
- These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on June 15, 2011. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on July 1, 2011, with the final installment vesting on June 1, 2014.
- These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on January 19, 2012. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2012, with the final installment vesting on January 1, 2015.
- These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on June 16, 2012. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on July 1, 2012, with the final installment vesting on June 1, 2015.
- These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on February 15, 2013. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on March 1, 2013, with the final installment vesting on February 1, 2016.
- These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 28, 2014. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2014, with the final installment vesting on January 1, 2017.

## Remarks:

/s/ Peter M. Macaluso

02/11/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.